Christchurch Medicines Information Service

There are over 240,000 people in NZ currently diagnosed with diabetes mellitus (mostly type 2), and possibly another 100,000 undiagnosed. In October 2018, vildagliptin became the first dipeptidyl peptidase-4 (DPP-4) inhibitor funded in NZ. It is one of a number of DPP-4 inhibitors used internatio...

Sacubitril + valsartan is now available in New Zealand and fully subsidised under Special Authority criteria. Eligible patients must have NYHA/WHO functional class II, III or IV heart failure; a left ventricular ejection fraction of <35%; and be receiving standard heart failure therapy. It can...

Compliance packs With an ageing population there is increasing incidence of multimorbidity and polypharmacy. This leads to complex dosing regimens. Compliance aids, such as the Medico Paks® or unit dose medication sachets, are widely used to manage complex medication regimes, and help remind...

Patients should be asked if they are wearing a transdermal patch prior to a magnetic resonance imaging (MRI) scan Background A recent case of possible fentanyl toxicity in a patient wearing a transdermal patch during an MRI highlighted the safety issues associated with medication patches in MR...